SCHEMBL2858460

SCHEMBL2858460

NCCN(C1CC1)S(=O)(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
ACHE P22303 1/20 0.44
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 4/20 0.43
F2 P00734 2/20 0.43
PRSS1 P07477 2/20 0.43
PRSS2 P07478 2/20 0.43
PRSS3 P35030 2/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13136198 0.81 THRB (0.47) KMT2AMEN1ACHENPC1ALDH1A1
SCHEMBL2865693 0.79 KMT2A (0.46) KMT2AMEN1ACHENPC1ALDH1A1
SCHEMBL1026059 0.77 KMT2A (0.68) KMT2AMEN1ALDH1A1F2PRSS1
SCHEMBL2825482 0.77 KMT2A (0.56) KMT2AMEN1ACHEALDH1A1MCOLN3
SCHEMBL13800054 0.75 KMT2A (0.48) KMT2AMEN1ACHENPC1ALDH1A1
SCHEMBL31520605 0.75 KMT2A (0.46) KMT2AMEN1ACHENPC1ALDH1A1
SCHEMBL1025251 0.75 KMT2A (0.53) KMT2AMEN1ALDH1A1F2PRSS1
SCHEMBL19898226 0.75 KMT2A (0.50) KMT2AMEN1ACHENPC1ALDH1A1
SCHEMBL19898225 0.75 KMT2A (0.50) KMT2AMEN1ACHENPC1ALDH1A1
SCHEMBL14815959 0.74 KMT2A (0.40) KMT2AMEN1ACHENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 KMT2A 922/4885MEN1 4666/4885ACHE 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.